2024
Neurosyphilis is characterized by a compartmentalized and robust neuroimmune response but not by neuronal injury
Catalano A, Yoon J, Fertuzinhos S, Reisert H, Walsh H, Kosana P, Wilson M, Gisslen M, Zetterberg H, Marra C, Farhadian S. Neurosyphilis is characterized by a compartmentalized and robust neuroimmune response but not by neuronal injury. Med 2024, 5: 321-334.e3. PMID: 38513660, PMCID: PMC11216317, DOI: 10.1016/j.medj.2024.02.005.Peer-Reviewed Original ResearchMarker of neuronal injuryNeuronal injuryNeurological symptomsWhite blood cell count <Immune responsePresence of neurological symptomsNeuroinflammatory diseasesCell count <CSF-VDRL testPlasma reagin titerCNS immune responsesCNS-specific immune responseImmune cell activationCSF inflammatory responseCSF cellsNeurosyphilis casesAsymptomatic neurosyphilisCSF neopterinImmune profileNeuroimmune responseHIV statusNational Institutes of HealthNeurosyphilisCell activationInflammatory response
2020
Longitudinal analyses reveal immunological misfiring in severe COVID-19
Lucas C, Wong P, Klein J, Castro TBR, Silva J, Sundaram M, Ellingson MK, Mao T, Oh JE, Israelow B, Takahashi T, Tokuyama M, Lu P, Venkataraman A, Park A, Mohanty S, Wang H, Wyllie AL, Vogels CBF, Earnest R, Lapidus S, Ott IM, Moore AJ, Muenker MC, Fournier JB, Campbell M, Odio CD, Casanovas-Massana A, Herbst R, Shaw A, Medzhitov R, Schulz W, Grubaugh N, Dela Cruz C, Farhadian S, Ko A, Omer S, Iwasaki A. Longitudinal analyses reveal immunological misfiring in severe COVID-19. Nature 2020, 584: 463-469. PMID: 32717743, PMCID: PMC7477538, DOI: 10.1038/s41586-020-2588-y.Peer-Reviewed Original ResearchConceptsSevere COVID-19Moderate COVID-19Immune signaturesDisease outcomeCOVID-19Disease trajectoriesInterleukin-5Early immune signaturesInnate cell lineagesType 2 effectorsT cell numbersPoor clinical outcomeWorse disease outcomesImmune response profileCoronavirus disease 2019Distinct disease trajectoriesCytokine levelsImmunological correlatesImmune profileClinical outcomesEarly elevationImmune profilingIL-13Immunoglobulin EDisease 2019